Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib
resistance and/or intolerance, as well as in the frontline setting in patients with chronic …

Several adaptor molecules bind to cytoplasmic tails of β-integrins and facilitate bidirectional
signaling, which is critical in thrombosis and hemostasis. Interfering with integrin-adaptor …

The most common drug-induced colitis reported in the literature is nonspecific colitis.
Nonspecific colitis is characterized endoscopically by the presence of colonic mucosal …

Dasatinib (DAS) is a potent inhibitor of the BCR-ABL, SRC, c-KIT, PDGFR, and ephrin
tyrosine kinases that has demonstrated only modest clinical efficacy in melanoma patients …

Gastrointestinal bleeding appears to be a common adverse event associated with dasatinib
therapy. Here we present a case of a 59‐year‐old man with chronic myeloid leukaemia …

The tyrosine kinase inhibitor dasatinib is often used after allogeneic hematopoietic cell
transplantation to treat minimal residual disease in Philadelphia chromosome–positive …

The Lyn tyrosine kinase governs the development and function of various immune cells, and
its dysregulation has been linked to malignancy and autoimmunity. Using models of …

Background and objective Ulcerative colitis is an inflammatory condition of the colon in the
gastrointestinal system. Currently, the most potent medications used for ulcerative colitis …

We report a rare case of haemorrhagic colitis attributed to dasatinib therapy in a 47-year-old
African-American woman who was diagnosed with extramedullary T-lymphoblastic …

Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states
associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase …